4.4 Article

GET MORE, PAY MORE? An elaborate test of construct validity of willingness to pay per QALY estimates obtained through contingent valuation

Journal

JOURNAL OF HEALTH ECONOMICS
Volume 31, Issue 1, Pages 158-168

Publisher

ELSEVIER
DOI: 10.1016/j.jhealeco.2011.09.004

Keywords

Willingness to pay; WTP; Contingent valuation; Sensitivity to scale; Validity; QALY

Funding

  1. Astra-Zeneca
  2. GlaxoSmithKline
  3. Janssen-Cilag
  4. Merck
  5. Pfizer BV

Ask authors/readers for more resources

Estimates of WTP per QALY can be taken as an indication of the monetary value of health gains, which may carry information regarding the appropriate height of the cost-effectiveness threshold. Given the farreaching consequences choosing a particular threshold, and thus the potential relevance of WTP per QALY estimates, it is important to address the validity of these estimates. This study addresses this issue. Our findings offer little support to the validity of WTP per QALY estimates obtained in this study. Implications for general WIT per QALY estimates and further research are discussed. (C) 2011 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available